Adr ratio change

July 15, 2025 biodexa pharmaceuticals plc (“biodexa” or the “company”) adr ratio change biodexa pharmaceuticals plc (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its american depositary receipts (“adr”) from one (1) adr representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) adr representing one hundred thousand (100,000) ordinary shares (the "ratio change"). the effective date of the ratio change is expected to be july 31, 2025.
BDRX Ratings Summary
BDRX Quant Ranking